Clinical trials: SARS-COV2
Solid Tumor, Sars-CoV2
Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
This study is for patients that are hospitalized for Coronavirus Disease 2019 (COVID-19). The purpose of this study is to see whether neutralizing interleukin-8 (IL-8) with BMS-986253 can help improve the health condition of…
- Conditions
- Solid Tumor, Sars-CoV2, Hematological Malignancy
- Trial name
- NCT04347226
- Testing
- BMS-986253
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Columbia University
Covid19, SARS-CoV Infection
A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults
This is a Phase 2, randomized, placebo-controlled, and observer-blind study in healthy adults. The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against COVID-19: As 2…
- Conditions
- Covid19, SARS-CoV Infection, Corona Virus Infection
- Trial name
- NCT04668339
- Testing
- ARCT-021 single dose priming, ARCT-021 two lower dose priming, ARCT-021 two higher dose priming
- Where
- 15 sites in United States, Singapore
- Volunteers
- 581 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
Healthy Participants
A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).
The purpose of the study is to learn about the safety and effects of a combined vaccine for RSV and COVID-19 when given with a seasonal flu vaccine or when given alone.
- Trial name
- NCT05886777
- Testing
- Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF
- Where
- 37 sites in United States
- Volunteers
- 1,142 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection
The primary objective of the study is to assess the virologic efficacy of REGN10933+REGN10987 across different intravenous and subcutaneous doses compared to placebo.
- Trial name
- NCT04666441
- Testing
- REGN10933+REGN10987 combination therapy
- Where
- 57 sites in United States
- Volunteers
- 1,149 people
- Sponsor
- Regeneron Pharmaceuticals
Systemic Allergic Reaction
The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose
Background: Some people have allergic reactions to COVID-19 mRNA vaccines. Researchers want to learn more about these reactions to provide guidance on who can safely receive the vaccines, including a second dose in people who had…
- Trial name
- NCT04977479
- Testing
- Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Pfizer-BioNTech COVID-19 Vaccine, Bivalent
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2
COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease
Primary Objectives Phase 1 (Safety and Tolerability) Evaluate the safety and tolerability of REGN14256+imdevimab and REGN14256 monotherapy, as measured by treatment-emergent adverse events (TEAEs), injection-site reactions…
- Trial name
- NCT05081388
- Testing
- REGN14256, imdevimab, casirivimab + imdevimab
- Where
- 28 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
COVID-19
COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE)
Background: People who are recovering from COVID-19 may continue to have problems that affect their daily life. For instance, they might feel overly tired.
- Trial name
- NCT04595773
- Testing
- Aerobic Exercise Training, Education
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
SARS-CoV Infection, Covid19
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
This is a randomized, observer-blinded, Phase 1/2 study evaluating the safety and immunogenicity of a quadrivalent HA nanoparticle influenza and SARS-CoV-2 rS nanoparticle combination vaccine with Matrix-M1 adjuvant; this…
- Trial name
- NCT04961541
- Testing
- ICC Vaccine, qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant, SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant
- Where
- 10 sites in Australia
- Volunteers
- 637 people, healthy volunteers welcome
- Sponsor
- Novavax
Long COVID, Chronic Fatigue Syndrome
Vagus Nerve Stimulation as Treatment for Long Covid
Many patients do not recover following Covid infection. The resulting illness is called Long Covid. Because there is no agreed upon treatment for this ailment, the research team has decided to do an open label pilot study using…
- Trial name
- NCT05608629
- Testing
- Transcutaneous Non-Invasive Vagus Nerve Stimulation
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
COVID
Use of Convalescent Plasma for COVID-19
The plan is to transfuse COVID-19 infected patients with convalescent plasma and observe whether this will result in a significant improvement in clinical outcome in comparison to historical experience.
- Trial name
- NCT04408040
- Testing
- Convalescent Plasma
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Northside Hospital, Inc.
COVID-19
Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).
The primary hypothesis to be tested is whether or not there is a difference in time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between PF-07321332/ritonavir and placebo.
- Trial name
- NCT05011513
- Testing
- PF-07321332, Ritonavir
- Where
- 225 sites in United States, Argentina and 18 more
- Volunteers
- 1,440 people
- Sponsor
- Pfizer
COVID-19, SARS-CoV 2
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19
The purpose of this study was to evaluate the efficacy of hydroxychloroquine (HCQ) and azithromycin (Azithro) to prevent hospitalization or death in symptomatic adult outpatients with COVID-19 caused by SARS-CoV-2 infection.
- Trial name
- NCT04358068
- Testing
- Hydroxychloroquine (HCQ), Azithromycin (Azithro)
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV 2
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications
To assess the efficacy and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding.
- Trial name
- CSSC-004 (NCT04373460)
- Testing
- SARS-CoV-2 convalescent plasma, Plasma from a volunteer donor
- Where
- 29 sites in United States
- Volunteers
- 1,225 people
- Sponsor
- Johns Hopkins University
COVID-19, SARS-CoV-2 Infection
Novel Experimental COVID-19 Therapies Affecting Host Response
The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing…
- Conditions
- COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
- Trial name
- NECTAR (NCT04924660)
- Testing
- TXA127, TRV027, Fostamatinib
- Where
- 51 sites in United States
- Volunteers
- 1,060 people
- Sponsor
- Sean Collins
Bioavailability
Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation
The purpose of this study is to estimate the relative bioavailability of PF-07321332 in different formulations in healthy adult participants.
- Trial name
- NCT05263895
- Testing
- PF-07321332/ritonavir, PF-07321332
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
SARS-CoV 2
Efficacy of Tocilizumab on Patients With COVID-19
This is a randomized, double blind, multi-center study to evaluate the effects of tocilizumab compared to placebo on patient outcomes in participants with confirmed SARS-CoV-2 infection and evidence of systemic inflammation.
- Trial name
- NCT04356937
- Testing
- Tocilizumab
- Where
- 3 sites in United States
- Volunteers
- 243 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma
COVID19 OutcomeS in Myeloma and the Impact of VaCcines
The COVID-19 pandemic has had an outsized impact on individuals with underlying social and medical vulnerability, leading to increased rates of severe disease, hospitalization, and death in these groups.
- Trial name
- COSMIC (NCT05831787)
- Testing
- Patient Reported Outcomes
- Where
- 2 sites in United States
- Volunteers
- 201 people
- Sponsor
- ASH Research Collaborative
COVID-19, Post Acute Sequelae of SARS-CoV-2
Mindfulness Intervention for Post-Covid Symptoms
The purpose of this study is to assess the feasibility of using a wearable brain-sensing wellness device (Muse-S) to potentially reduce stress and anxiety during Post-Covid, which is characterized by increased stress and anxiety.
- Trial name
- NCT05199233
- Testing
- Muse S™ Headband system
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Mayo Clinic
SARS-CoV-2
Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial
This is a pragmatic randomized open-label study of the safety and efficacy of the combination of colchicine and Rosuvastatin in addition to standard of care (SOC) compared to SOC alone in hospitalized patients with SARS-CoV-2
- Trial name
- COLSTAT (NCT04472611)
- Testing
- Standard of Care (SOC) and Colchicine+Rosuvastatin
- Where
- 4 sites in United States
- Volunteers
- 250 people
- Sponsor
- Yale University
COVID-19
Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older
The primary objectives of the study are: To describe the safety profile of all participants in each age group and each study intervention group up to 12 months post-last dose.
- Trial name
- VAW00001 (NCT04798027)
- Testing
- SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company